Synaptogenix (SNPX) Competitors $7.22 -0.49 (-6.36%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. BTAI, MDCX, LVTX, DYAI, GRCE, VRCA, LIMN, OKUR, KLTO, and XFORShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include BioXcel Therapeutics (BTAI), Medicus Pharma (MDCX), LAVA Therapeutics (LVTX), Dyadic International (DYAI), Grace Therapeutics (GRCE), Verrica Pharmaceuticals (VRCA), Liminatus Pharma (LIMN), OnKure Therapeutics (OKUR), Klotho Neurosciences (KLTO), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors BioXcel Therapeutics Medicus Pharma LAVA Therapeutics Dyadic International Grace Therapeutics Verrica Pharmaceuticals Liminatus Pharma OnKure Therapeutics Klotho Neurosciences X4 Pharmaceuticals BioXcel Therapeutics (NASDAQ:BTAI) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Which has more risk & volatility, BTAI or SNPX? BioXcel Therapeutics has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Do institutionals & insiders hold more shares of BTAI or SNPX? 30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 21.2% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation and earnings, BTAI or SNPX? Synaptogenix has lower revenue, but higher earnings than BioXcel Therapeutics. Synaptogenix is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.27M19.08-$59.60M-$12.64-0.21SynaptogenixN/AN/A-$12.77M-$10.08-0.72 Does the media refer more to BTAI or SNPX? In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. BioXcel Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score. Company Overall Sentiment BioXcel Therapeutics Neutral Synaptogenix Neutral Do analysts prefer BTAI or SNPX? BioXcel Therapeutics currently has a consensus target price of $39.75, suggesting a potential upside of 1,369.50%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 2 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.43Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BTAI or SNPX more profitable? Synaptogenix has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -5,869.82%. BioXcel Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-5,869.82% N/A -134.45% Synaptogenix N/A -115.28%-58.31% SummaryBioXcel Therapeutics beats Synaptogenix on 9 of the 14 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.04M$12.30B$9.08B$10.58BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.7221.9786.1627.45Price / SalesN/A273.38539.92202.26Price / CashN/A47.1237.9261.55Price / Book1.6710.2813.056.77Net Income-$12.77M-$52.40M$3.30B$275.88M7 Day Performance13.70%6.10%4.55%2.63%1 Month Performance15.15%15.74%9.73%9.10%1 Year Performance142.28%32.50%85.10%35.69% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenixN/A$7.22-6.4%N/A+143.1%$10.04MN/A-0.724News CoverageGap UpBTAIBioXcel Therapeutics4.0583 of 5 stars$2.68+7.0%$39.75+1,386.0%-70.1%$42.81M$2.27M-0.2190Analyst ForecastGap UpMDCXMedicus Pharma2.6529 of 5 stars$2.40-0.8%$23.50+879.2%N/A$42.77MN/A-1.79N/AAnalyst ForecastLVTXLAVA Therapeutics1.5179 of 5 stars$1.62flat$2.69+65.7%-3.7%$42.62M$11.98M-1.5460Analyst ForecastDYAIDyadic International2.6003 of 5 stars$1.17+2.7%$6.00+412.4%-4.2%$42.38M$3.49M-6.167Analyst ForecastGap UpGRCEGrace Therapeutics1.8723 of 5 stars$3.03+0.3%$12.00+296.0%N/A$41.91MN/A-3.52N/APositive NewsAnalyst ForecastShort Interest ↑VRCAVerrica Pharmaceuticals3.7933 of 5 stars$4.41-4.4%$60.00+1,262.1%-65.5%$41.62M$7.57M-0.5340News CoverageAnalyst ForecastGap DownLIMNLiminatus PharmaN/A$1.60+1.3%N/AN/A$41.62MN/A0.00N/APositive NewsEarnings ReportAnalyst ForecastOKUROnKure Therapeutics3.299 of 5 stars$3.00+0.5%$32.33+976.3%N/A$40.64MN/A-0.63N/AAnalyst ForecastKLTOKlotho Neurosciences0.6456 of 5 stars$0.56-4.9%N/AN/A$39.73MN/A-1.26N/AAnalyst ForecastGap DownXFORX4 Pharmaceuticals3.9625 of 5 stars$3.45+0.2%$34.17+891.5%-79.5%$39.54M$2.56M-0.2380Analyst Forecast Related Companies and Tools Related Companies BioXcel Therapeutics Alternatives Medicus Pharma Alternatives LAVA Therapeutics Alternatives Dyadic International Alternatives Grace Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Liminatus Pharma Alternatives OnKure Therapeutics Alternatives Klotho Neurosciences Alternatives X4 Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
